


PRODUCT INFORMATION



Revaprazan (hydrochloride)

Item No. 46259

CAS Registry No.: 178307-42-1
Formal Name: 4-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-N-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine, monohydrochloride
Synonyms: SB-641257, YH 1885
MF: C₂₂H₂₃FN₄ • HCl
FW: 398.9
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Revaprazan (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the revaprazan (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Revaprazan (hydrochloride) is sparingly soluble (1-10 mg/ml) in a 1:1 solution of acetonitrile:water.

Description

Revaprazan is a potassium-competitive acid blocker (P-CAB) that inhibits H⁺/K⁺-ATPase activity in porcine gastric mucosa membrane vesicles (IC₅₀ = 0.35 μM).¹ It rescues *H. pylori*-induced cytotoxicity and *H. pylori*-induced increases in prostaglandin E₂ (PGE₂; Item No. 14010) levels in AGS gastric epithelial cells, and it potentiates the antifungal activity of posaconazole (Item No. 14737) against *Aspergillus* *in vitro*.^{2,3} Revaprazan decreases disease severity in a rat model of indomethacin-induced intestinal damage.⁴ Formulations containing revaprazan have been used in the treatment of gastritis and gastric and duodenal ulcers.

References

1. Yoon, Y.A., Park, C.S., Cha, M.H., *et al.* Novel pyrimidines as acid pump antagonists (APAs). *Bioorg. Med. Chem. Lett.* **20**(19), 5735-5738 (2010).
2. Lee, J.-S., Cho, J.-Y., Song, H., *et al.* Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against *Helicobacter pylori*-induced COX-2 expression by inactivating Akt signaling. *J. Clin. Biochem. Nutr.* **51**(2), 77-83 (2011).
3. Cheng, W., Shen, M., Wan, L., *et al.* In vitro combination effects and mechanisms of Revaprazan with triazole antifungal drugs on *Aspergillus*. *BMC Microbiol.* **25**(1), 715 (2025).
4. Han, Y.M., Park, J.M., Her, S., *et al.* Revaprazan prevented indomethacin-induced intestinal damages by enhancing tight junction related mechanisms. *Biochem. Pharmacol.* **182**, 114290 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/18/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM